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Holder pasteurization (62. 5◦C for 30min) is recommended by all international human
milk bank guidelines to prevent infections potentially transmitted by donor human milk.
A drawback is that it affects some human milk bioactive and nutritive components.
Recently, High Temperature-Short Time (HTST) pasteurization has been reported to be
a valuable alternative technology to increase the retention of some biological features
of human milk. Nevertheless, to date, few data are available about the impact of
pasteurization methods other than Holder on the antiviral activity of human milk. The
present study was aimed at evaluating the antiviral activity of human milk against
a panel of viral pathogens common in newborns and children (i.e., herpes simplex
virus 1 and 2, cytomegalovirus, respiratory syncytial virus, rotavirus, and rhinovirus),
and at assessing the effect of Holder and HTST pasteurization on milk’s antiviral
properties. The results indicate that human milk is endowed with antiviral activity against
all viruses tested, although to a different extent. Unlike the Holder pasteurization,
HTST preserved the inhibitory activity against cytomegalovirus, respiratory syncytial
virus, rotavirus and herpes simplex virus type 2. By contrast, both methods reduced
significantly the antiviral activities against rhinovirus and herpes simplex virus type 1.
Unexpectedly, Holder pasteurization improved milk’s anti-rotavirus activity. In conclusion,
this study contributes to the definition of the pasteurization method that allows the best
compromise between microbiological safety and biological quality of the donor human
milk: HTST pasteurization preserved milk antiviral activity better than Holder.
Keywords: human milk, HTST, Holder, antiviral activity, virus, pasteurization
INTRODUCTION
A mother’s own milk is the first choice for improving the short- and long-term outcomes for
all newborns, including preterm infants (1, 2). When a mother’s own milk is unavailable or
in short supply, a common occurrence in Neonatal Intensive Care Units, the World Health
Organization and the American Academy of Pediatrics recommend the use of donor milk (DM)
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as the best alternative (2, 3). Human milk (HM) can
be considered a species-specific dynamic biological system,
known to encompass many kinds of biological functions,
including antimicrobial and antiviral properties (2). It is
generally agreed that breastfeeding reduces the rate of serious
gastroenteritis, especially caused by rotaviruses (HRoVs), and
infant respiratory infections, as well as otitis media. The main
viruses involved in infant respiratory and middle ear infections
are respiratory syncytial virus (RSV) and rhinoviruses (HRhV)
(4–7). Furthermore, most herpetic infections are acquired during
childhood and their infection is lifelong. The vast majority
of herpes simplex virus 1 (HSV-1) infections are oral-labial
herpes and they are mainly transmitted by oral-to-oral contact.
By contrast, neonatal herpes can occur when an infant is
exposed to herpes simplex virus 2 (HSV-2) in the genital tract
during delivery. The risk for neonatal herpes is greatest when
a mother acquires HSV infection for the first time in late
pregnancy (8). Human cytomegalovirus (HCMV) is another
herpesvirus, responsible for the most common congenital
infection worldwide, affecting 1 out of every 150 live-born infants
worldwide (9).
Several specific bioactive and immunomodulatory factors
play a role in the milk-mediated defense system against viral
infections, including milk proteins, as lactoferrin, lactadherin,
lactoperoxidase, lysozyme, and secretory immunoglobulins A
(sIgA), but also mucins, sulfated glycolipids, glycosaminoglycans
and vitamin A (6, 10–12). Despite the presence of protective
factors in HM, some viruses, as human immunodeficiency virus
type 1, human T-lymphotrophic virus, zikavirus, and HCMV, are
transmitted from mother to infant thus the heat treatment of
DM is mandatory in human milk banks (HMBs) to guarantee
microbiological safety (13). The ESPGHAN Committee on
Nutrition has recently advised that “future research should focus
on the improvement of milk processing in HMBs, particularly
of heat treatment” (14). Currently, a pasteurization process at
62.5◦C for 30min (the Holder pasteurization method, HoP) is
recommended in all international guidelines for the constitution
of HMBs (13, 15). However, literature indicates that HoP
affects several milk components to variable degrees, with a
marked effect on milk protein content and activity (16, 17).
Therefore, HMBs and researchers are committed to developing
novel or enhanced methods to process DM that can ensure
microbial inactivation, while improving the preservation of its
nutritional, immunological, and functional constituents (14).
High Temperature Short Time pasteurization (HTST) was the
first non-HoP technique tested to improve the nutritional and
immunological quality of milk, because it has been established
in the dairy industry since the 1930s. HTST in food industry is
usually performed by heating thin-layered milk in continuous
flow systems at 72◦C for 15 seconds, although high variability on
the processing equipment and conditions was recently observed
for HTST when applied to HM pasteurization (18). On the basis
of the existing evidence, a new small-scale continuous-flowHTST
pasteurizer was recently designed and validated for treating HM
by our group (19).
The present research is aimed at assessing whether and to
which extent HoP and HTST have an effect on the antiviral
properties of raw HM against a panel of viral pathogens causing
diseases in newborns and children, as HSV-1, HSV-2, HCMV,
RSV, HRhV, and HRoV.
MATERIALS AND METHODS
HM Samples Collection
HM samples were obtained from the HMB of the Città della
Salute e della Scienza of Turin, Italy. An ethical review process
was not required for this study, because it was not a clinical
trial. Each milk donor involved in this research signed a written
consent form, where mother’s and infant’s data protection was
assured. Besides, donors where informed that only milk samples
stored in excess to the needs of their infants should have
been used for research purposes explaining the study design.
Two pools of milk were obtained on two different occasions.
Both pools (final volume 250ml) included colostrum (days 1–
5 postpartum), transitional milk (days 6–14 postpartum), and
mature milk (beyond day 15 postpartum). Each pool contained
milk samples from three donors. The donors of the first pool
were different from those of the second pool. The donors
cleaned their hands and breasts according to the Italian HMB
guidelines (13). The milk specimens were collected in sterile
bisphenol-free polypropylene bottles using a breast pump and
stored by the HMB at −20◦C until processed. The individual
specimens were thawed overnight in refrigerated conditions,
and then pooled rapidly in the morning in the HMB, and
shipped refrigerated within 1 h. Upon arrival, pooled samples
were processed according to the appropriate technique, and
immediately separated in 10-ml aliquots, which were conveyed to
the analyzing laboratory within 1 h. Raw milk was also aliquoted
immediately after collection and stored as fresh and/or frozen
material, as required.
Milk Pasteurization
The milk samples were processed using either HoP or HTST
system. HoP was performed directly in sterile bisphenol-
free polypropylene bottles using a standard HM pasteurizer
(Metalarredinox, BG, Italy). HTST was performed using a
patented proprietary device (European Patent n◦ 2974603),
as previously described (19, 20). HTST-pasteurized milk was
collected in sterile bisphenol-free polypropylene bottles. Four mL
from each sample were skimmed by centrifugation at 2,000 g for
30min at 4◦C in sterile tubes (Eppendorf S.r.l, Milan, Italy), and
then shipped refrigerated within 1 h to the laboratory for antiviral
assays.
Cells
African green monkey kidney cells (Vero) (ATCC CCL-81)
and human epithelial cells Hep-2 (ATCC CCL-23) were grown
as monolayers in Eagle’s minimal essential medium (MEM)
(Gibco/BRL) supplemented with heat-inactivated 10% fetal
calf serum (FCS) (Gibco/BRL) and 1% antibiotic-antimycotic
solution (Zell Shield, Minerva Biolab) at 37◦C in an atmosphere
of 5% of CO2. Human Foreskin Fibroblasts (HFF-1) (ATCC
SCRC-1041) at low-passage-number (<30), African green
monkey kidney epithelial cells (MA104) and human epithelial
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adenocarcinoma HeLa cells (ATCC CCL-2) were propagated in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich)
supplemented with FCS and antibiotic-antimycotic solution.
Viruses
The neurovirulent strains LV (21) and MS (ATCC VR-540) of
HSV-1 and HSV-2, were propagated in Vero cells at 37◦C (22).
HRhV 1A (ATCC VR-1559) was propagated in HeLa cells, at
33◦C. HSV-1, HSV-2, and HRhV titers were determined by
the standard plaque method and expressed as plaque-forming
unit (PFU)/ml. A bacterial artificial chromosome (BAC)-derived
HCMV strain Towne incorporating the green fluorescent protein
(GFP) sequence (23) was propagated on HFF-1 and viral titres
were determined by fluorescent focus assay. RSV strain A2
(ATCC VR-1540) was propagated in Hep-2 and titrated by the
indirect immunoperoxidase staining procedure using an RSV
monoclonal antibody (Ab35958, Abcam) (24). Human HRoV
strain Wa (ATCC VR-2018) was activated with 5µg/ml of
porcine pancreatic trypsin type IX (Sigma) for 30min at 37◦C
and propagated in MA104 cells by using MEM containing 0.5 µg
of trypsin per ml. HCMV, RSV and HRoV titers were expressed
as focus-forming units (FFU)/ml. Virus stocks were maintained
frozen (-80◦C).
Viral Inhibition Assay
Antiviral activity of milk samples was determined by plaque
reduction assays for HSV-1, HSV-2, and HRhV and by focus
reduction assays for HCMV, RSV, and HRoV. Antiviral assays
were performed by incubating serial dilutions of milk (from 1/1
to 1/1024 parts in medium) with virus for 1 h at 37 ◦C and
then the mixtures were added to cells for 2 h at 37◦C. After
three washings with medium, monolayers were overlaid with
1.2%-methylcellulose medium with 2% FCS. The effect on HSV
and HRhV infections was evaluated on pre-seeded Vero or Hela
cells (10 × 104) respectively, in 24-well plates infected with 200
PFU/well of HSV or 30 PFU/well of HRhV; after incubation for
24 h (HSV-2 and HRhV) or 48 h (HSV-1) cells were fixed and
stained with 0.1% crystal violet in 20% ethanol and viral plaques
were counted. The mean plaque count for each sample dilution
was expressed as a percentage of the mean plaque count of the
control (25). In HCMV inhibition assay, cells pre-seeded in 96-
well plates at a density of 5.0 × 103/well, were infected with
140 PFU/well of GFP-coding HCMV. After 5-day-incubation at
37◦C 5% CO2 atmosphere, infected cells were visualized as green
fibroblasts using fluorescence microscopy and counted. In RSV
and HRoV inhibition assays, Hep-2 cells and MA104 were pre-
seeded at a density of 1 × 104/well and 1.4 × 104, respectively,
in 96-well plates. Cells were infected with 60 PFU/well of RSV or
200 PFU/well of HRoV and, after 16 h (HRoV) or 3 days post-
infection (RSV), infected cells were fixed with cold methanol and
acetone for 1min and subjected to virus-specific immunostaining
as described previously (26, 27). Fluorescent and immunostained
viral foci were microscopically counted and results were reported
as percentages of foci in comparison to controls. The endpoints
of the assays were the effectivemilk dilution that reduced the viral
plaque/focus formation by 50% (inhibitory dilution-50, ID50)
in comparison to that in the untreated control. The ID50 of
milk was calculated by using the program PRISM 4 (GraphPad
Software) to fit a variable slope-sigmoidal dose–response curve.
All data were generated from duplicate wells in at least three
independent experiments on each HM pool.
Cell Viability Assay
Cell viability was measured by the MTS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] assay. Confluent cell cultures seeded in 96-well
plates were incubated with different dilutions of milk in
triplicate under the same experimental conditions described
for the antiviral assays. Cell viability was determined by the
CellTiter 96 Proliferation Assay Kit (Promega) according to the
manufacturer’s instructions. Absorbances were measured using
a Microplate Reader (Model 680, BIORAD) at 490 nm. Their
effect on cell viability at different milk dilutions was expressed
as a percentage, by comparing the absorbances of treated cells
with that of the cells incubated with culture medium alone. The
50%-cytotoxic dilutions (CD50) and 95% confidence intervals
(CIs) were determined with Prism 4 software.
Statistical Analysis
Statistical analysis was performed using Extra sum-of-square F
test as reported in legends of figures, on GraphPad software.
Significance was reported for p < 0.05.
RESULTS AND DISCUSSION
Antiviral Activity of HM
This paper reports on the antiviral activity of raw milk and
investigates the impact of two pasteurization techniques on
such biological property. The first set of experiments was
dedicated to assess the antiviral activity of two HM raw
milk pools against a panel of viral pathogens causing diseases
in newborns and children, and representing different viral
structures and families: enveloped DNA viruses, as HSV-1, HSV-
2, and HCMV (Herpesviridae family); enveloped RNA viruses, as
RSV (Paramyxoviridae family); naked single strand RNA virus, as
HRhV (Picornaviridae family); naked double strand RNA virus,
as HRoV (Reoviridae family). Figure 1A reports the antiviral
activity of the two HM pools, expressed as ID50, i.e., the dilution
of milk sample inhibiting the 50% of infectivity. The results
revealed that both pools exhibited antiviral activity against all
viruses with ID50 ranging from 0.010 to 0.183. As for the viruses
belonging to the Herpesviridae family, both pools exhibited a
similar antiviral activity against HCMV, whereas a statistically
significant difference in anti-HSV-1 and anti-HSV-2 activity was
observed (p < 0.05). These results confirm previous findings that
HM samples were endowed with anti-HCMV activity, although
to a different extent from sample to sample and from mother to
mother (6, 28). Our data evidenced a high activity against HSV-
1 and HSV-2, in contrast with other studies that observed weak
or no antiviral effect (29–31) for raw HM, whereas, when HM
samples were aspirated from the stomachs of the infants within
few hours of feeding, they were reported to reduce HSV-1 titers
(31). The observed inhibitory activity of milk pools with ID50
around of 0.01 against RSV and 0.05 against HRhV supports
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FIGURE 1 | (A) Antiviral activities against HSV-1, HSV-2, HCMV, RSV, HRhV, and HRoV are reported as inhibitory dilution-50 (ID50) values for raw human milk pool #1
(white) and pool #2 (black bar). Data are reported as mean ID50 ± 95% confidence intervals of 4 independent experiments. ID50 values were compared using the
sum-of-squares F-test. ***P < 0.001; n.s., not significant. (B) Representative examples of plaque reduction assays and fluorescence foci assays of antiviral assays
treating infected cells with raw milk samples at a 1:2 dilution, an inhibitory dilution-100 (ID100) for all viruses. Untreated infected (upper row) and milk-treated infected
(lower row) fields are reported for HSV-1, HSV-2, HCMV, RSV, HRhV, and HRoV. HSV-1, HSV-2 and HRhV plaques were visualized after crystal violet staining; RSV
and HRoV foci were visualized by ICC (magnification 40X). HCMV fluorescent foci were visually counted as green cells at fluorescence microscopy (magnification
100X). HSV-1, HSV-2, and HRhV plaques are violet; HCMV infected cells are green; RSV and HRoV foci are brown.
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clinical observations that maternal milk protects infants against
respiratory infections, as bronchiolitis, during the first year of
life, and encourages breastfeeding as an effective/inexpensive
measure of prevention of lower respiratory tract infections in
infancy (32, 33). However, a variable antiviral activity of HM was
observed against different HRhV serotypes circulating worldwide
(6). Although the anti-HRoV activity of lactoferrin and of
milk fat globule membrane components that contains bioactive
glycoproteins and glycolipids has been widely reported in the
past, Pfaender et al. did not evidence a pronounced reduction
in viral titers of HRoV by HM (30, 34). By contrast, our study
reports a clear anti-HRoV effect for both milk pools, supporting
protection of breastfed children against gastrointestinal viral
infection. The differences in the serostatus of the donor mothers
for each virus along with the interpersonal variability in the
content of antiviral components of HMmay explain the different
extents of antiviral potencies between the two HM pools, and
some inconsistencies with previous literature. Figure 1B shows
representative images of the total inhibitory effect of raw milk
at a 1:2 dilution against all tested viral infections. Of note, all
the antiviral activities were not a consequence of cytotoxicity of
HM samples, since the CD50 of milk was one or two logarithms
greater than the ID50 (data not shown).
Effect of Hop and HTST Methods on
Antiviral Activity of HM
The main aim of this work was to assess the impact of
two pasteurization methods, HoP and HTST, on the antiviral
properties of raw HM. Therefore, in a second set of experiments,
aliquots of the HM pools were pasteurized in parallel or left
untreated and their antiviral activity was evaluated. Figure 2
FIGURE 2 | Raw milk (white), Holder pasteurized (HoP, black bar) and HTST pasteurized milk (horizontal striped bar) activities against HSV-1 (A), HSV-2 (B), HCMV
(C), RSV (D), HRhV (E), and HRoV (F) are reported as a mean ID50 ± 95% confidence intervals of two milk pools. Each pool was tested in 4 independent
experiments. ID50 values were compared using the sum-of-squares F-test. **p < 0.01; ***P < 0.001; n.s., not significant.
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reports the average of ID50 of the two pools, untreated or
pasteurized. The results evidenced a statistically significant
reduction of milk antiviral activity following HoP pasteurization
against HSV-1, HSV-2, HCMV, RSV, and HRhV infections.
These findings may reflect the reduction of specific components
with significant immunologic and anti-infective action, such as
immunoglobulins and lactoferrin, caused by HoP (16, 17). By
contrast, HTST preserved the inhibitory activity of raw milk
against most of the tested viruses: no significant difference was
evidenced between the ID50 of raw and HTST treated HM
samples against HSV-2, HCMV, RSV, and HRoV (Figure 2).
These data are consistent with previous reports showing that
HTST is better than HoP at preserving some biological HM
properties, including the antioxidant potential, the lactoferrin
content and structure, B and C vitamins, and some cytokines
(18). In this experiment, the reliability of such higher biological
activity retention is increased by the use of a patented equipment
that has a technology readiness level (TRL) of 6, which was
directly compared to a commercial HoP device normally used
in HMBs. Figure 2 also showed that HoP and HTST similarly
reduced the antiviral activities against HSV-1 and HRhV
compared to untreated milk. Unexpectedly, HM anti-HRoV
activity was increased by HoP treatment with an ID50 value of
0.014 for pasteurized milk against an ID50 value of 0.04 of raw
HM. Although we do not have an explanation for this result, we
can speculate that thermal treatment at 62.5◦C for 30min may
alter the structure of some HM components thereby increasing
their protective activity, such as the release of specific peptides
active against HRoV following protein degradation.
CONCLUSION
This study demonstrated that raw HM is endowed with antiviral
activity in vitro against viral pathogens causing infections
in newborns and children. Further studies are needed to
investigate the clinical relevance of this activity. HoP method,
currently recommended in international guidelines for HMBs,
proved to significantly decrease the antiviral activity against
HSV-1, HSV-2, HCMV, RSV, and HRhV but not against
HRoV. By contrast, HTST preserved antiviral properties of
raw HM against four out of six viruses analyzed. These data,
along with previous literature, support the HTST as a valid
alternative to HoP. Despite the fact that HTST provides a
thermal treatment at a higher temperature than HoP (72
vs. 62.5◦C, respectively), the far more rapid heating and
cooling time of HTST (seconds instead of minutes, respectively)
could improve the quality of the final product. This may
make HTST suitable for providing the best compromise
betweenmicrobiological safety and preservation of key biological
components and properties of HM, including its antiviral
activity.
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